CanaQuest Medical Corp. news

CanaQuest Medical Corp (“CanaQuest” or the “Company”) (O

NHL Alumni Association (NHLAA), NEEKA Health Canada("NEEKA"),and CanaQuest Medical Corp ("CanaQuest") are pleased to announce a transformative study partnership that will investigate the efficacy of Mentanine® as a potential treatment to reduce anxiety in former NHL

We believe we can provide a safer alternative to other THC products providing the benefits without the negative psychiatric side effects. Pre-clinical trials have demonstrated the reversal of depression-like and schizophrenia-related symptoms, blockage of memory impairment, hyperactive activity, and gene vulnerability.

CanaQuest Medical Corp ("CanaQuest" or the "Company") (OTC:CANQF), a

Canaquest Medical Corp (OTC PINK:CANQF) (the "Company" or "CanaQuest"), a clinical-stage life sciences company focused on drug discovery and development of next-generation targeted cannabinoid therapeutics for the central nervous system (CNS), today announced that it has been awarded the Best Global Medical Cannabinoid Development Company 2023, in its eighth annual Healthcare and Pharmaceutical Awards by Global Health & Pharma, United Kingdom, a glo

Canaquest Medical Corp (OTC:CANQF) (the "Company" or "CanaQuest"), a clinical-stage life sciences company focused on drug discovery and development of next-generation targeted cannabinoid therapeutics for the central nervous system (CNS), today announced the signing of a Master Service Agreement with Neeka Health (“Neeka”) that will encompass multiple clinical studies to evaluate the efficacy of M

Canaquest Medical Corp (OTC PINK:CANQF) (the “Company” or “CanaQuest“), an award-winning, Clinical Stage/Life-Sciences company focused on drug discovery and development of next-generation targeted therapeutics within the endocannabinoid system and specific brain receptors, today announced its US launch of all-natural Mentanine (cannabidiol “CBD” + IP, Omega-3s, DHA, EPA formula) in Californi

Canaquest Medical Corp (OTC Pink:CANQF) (the "Company" or "CanaQuest"), an award-winning, Clinical Stage/Life-Sciences company focused on drug discovery and development of next-generation targeted therapeutics within the endocannabinoid system and specific brain receptors, today announced its US launch of all-natural Mentanine® (cannabidiol "CBD" + IP, Omega-3s, DHA, EPA formula) in California for distribution across the United States and international ex

Pharmaceutical: We are perfecting our CQ-001 Drug Candidate (CBD based IP formula) delivery system for Epilepsy in readiness for another Clinical Study for efficacy at the Ontario Brain Institute “OBI”……targeting September.

Our first Clinical Study at OBI already achieved a 20% reduction in seizures……..we believe we can do better with our more concentrated formula.

Nutraceutical: Our

Canaquest Medical Corp (OTC PINK:CANQF) (the “Company” or “CanaQuest“), an award-winning Life Science/Pharmaceutical company developing formulations combining cannabinoid molecules with pharmaceutical-grade botanical compounds, today announced the filing of its International Patent, trade named Mentanine, which has demonstrated at least 10-times (10X) the effica

Canaquest Medical Corp (OTC PINK:CANQF) (the “Company” or “CanaQuest“), an award-winning Life Science/Pharmaceutical company developing health and wellness products combining cannabinoid molecules with pharmaceutical-grade botanical compounds, today announced that Rob Rinderman has joined CanaQuest as its new Director of Communications. Mr. Rinderman will focus on managing a proactive investor relations and corporate communications program, further expanding inves